Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNanoco Regulatory News (NANO)

Share Price Information for Nanoco (NANO)

Share Price is delayed by 15 minutes
Get Live Data
2.47    0.27 (12.27%)
Bid:
2.30
Ask:
2.47
Spread: 0.17 (7.391%)
Market Cap: £4.51m
NANO Live PriceLast checked at - London Stock Exchange

Intraday Nanoco Share Chart

Director/PDMR Shareholding

22 Dec 2016 15:55

RNS Number : 6520S
Nanoco Group PLC
22 December 2016
 

For immediate release 22 December 2016

 

 

NANOCO GROUP PLC

("Nanoco" or the "Company" or "Group")

 

Director/PDMR Shareholding

 

The Company received notification today that, on 21 December 2016, Dr Michael Edelman, Nanoco's Chief Executive Officer, sold 380,000 ordinary shares and transferred 120,000 ordinary shares of £0.10 each in the Company ("Ordinary Shares") to meet charitable and other financial commitments before the end of the US tax year on 31 December 2016. The average sale price was 40.75 pence per share.

Following this transaction, Michael Edelman has a beneficial interest in 4,931,615 Ordinary Shares, representing approximately 2.07% per cent. of the total voting rights in the Company.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

 1

Details of the person discharging managerial responsibilities/person closely associated

 

a)

Name

Michael Edelman

 

2

Reason for the notification

 

a)

Position/status

 

CEO

b)

Initial notification/Amendment

 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

Name

 

Nanoco Group plc

b)

LEI

213800HOSJEZO1KOCV33

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

Description of the financial instrument, type of instrument

 

Ordinary Shares of £0.10 each

 

Identification code

 

 

ISIN GB00B01JLR99

 

b)

Nature of the transaction

Sale and transfer of Ordinary Shares

 

c)

Price(s) and volume(s)

 

Sale:

 

Volume

Price, p

344,057

40.5p

31,166

43.0p

4,777

44.0p

 

 

Transfer:

Volume(s) 120,000 Ordinary Shares

Price(s) 44.5p transfer price (no cash received for charitable donation)

 

 

d)

Aggregated information

 

Sale;

Volume 380,000 Ordinary Shares

Average Price 40.75 pence

 

 

Transfer:

Volume 120,000 Ordinary Shares

Price 44.5p transfer price (no cash received for charitable donation)

 

e)

Date of transaction

21 December 2016

 

f)

Place of transaction

London Stock Exchange (XLON)

 

 

 

 

 

For further information, please contact:

 

Nanoco

Tel: +44 (0) 161 603 7900

Michael Edelman, Chief Executive Officer

 

David Blain, Chief Financial Officer

 

Caroline Watson, Investor Relations Manager

Tel: + 44 (0) 7799 897357

cwatson@nanocotechnologies.com

 

 

 

 

 

Buchanan

 

 

Tel: +44 (0) 20 7466 5000

Mark Court / Sophie Cowles / Stephanie Watson

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHAKBDQPBDDOBB
Date   Source Headline
9th Jun 20267:00 amRNSGlass Lewis recommendation
5th Jun 202611:55 amRNSTR-1: Notification of major holdings
27th May 20267:00 amRNSIntention to delist from London Stock Exchange
20th Apr 20265:37 pmRNSDirector/PDMR Shareholding
20th Apr 20267:00 amRNSInterim Results
13th Apr 20267:00 amRNSNotice of Results
26th Mar 20267:00 amRNSShoei Litigation Conclusion
19th Mar 20267:00 amRNSStay of Shoei Litigation
23rd Feb 20267:00 amRNSShoei Litigation Update
26th Jan 20267:00 amRNSConclusion of CDX process & Directorate changes
15th Jan 20261:08 pmRNSReceipt of Litigation Proceeds
13th Jan 20264:50 pmRNSResult of AGM
12th Jan 20267:00 amRNSLitigation update
9th Dec 20257:00 amRNSBlocklisting Six-Monthly Return
8th Dec 202511:16 amRNSNotice of AGM
27th Nov 20257:00 amRNSResponse to non-infringement claim
26th Nov 20257:00 amRNSAnnual Report and Accounts
20th Nov 20257:00 amRNSLitigation outcome – Settlement agreed
18th Nov 20257:07 amRNSPreliminary Results
13th Nov 20257:00 amRNSNotice of Results
4th Nov 20257:06 amRNSExtension of Joint Development Agreement
15th Oct 20257:00 amRNS-RAwarding of Government Grant
30th Sep 20254:30 pmRNSTotal Voting Rights and Share Capital
8th Sep 20257:00 amRNSIssue of Equity and Director/PDMR Shareholdings
19th Aug 20257:00 amRNSFull Year Trading Update & Director Retirement
9th Jun 20257:00 amRNSBLOCKLISTING SIX-MONTHLY RETURN
28th Apr 202510:48 amRNSJoint Development Agreement
25th Apr 20257:00 amRNSPatent infringement lawsuit against LG
17th Apr 20253:54 pmRNSHigh Court Confirmation of Capital Reduction
15th Apr 20257:00 amRNSInterim Results & Investor Presentation
13th Mar 20257:00 amRNSNotice of Results
21st Jan 20252:20 pmRNSAnnual General Meeting – Voting Results
18th Dec 20248:26 amRNSDirector/PDMR Shareholding
13th Dec 20241:23 pmRNSResult of General Meeting
9th Dec 20247:00 amRNSBlock Listing Six Monthly Return
6th Dec 20246:30 pmRNSNotice of AGM
29th Nov 20247:00 amRNSGlass Lewis and ISS recommendations
28th Nov 20243:23 pmRNSDirector/PDMR Shareholding
28th Nov 20241:25 pmRNSDirector/PDMR Shareholding
25th Nov 20247:00 amRNS2024 Annual Report
20th Nov 20247:00 amRNSPreliminary Results
15th Nov 202411:00 amRNSPosting of Circular and Notice of General Meeting
30th Oct 20247:01 amRNSCompletion of Buyback Programme
30th Oct 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
29th Oct 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
28th Oct 20247:00 amRNSReceipt of General Meeting Requisition Notice
23rd Oct 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
22nd Oct 20247:00 amRNSAppointment of CEO and Notice of Results
22nd Oct 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
21st Oct 20247:00 amRNSTransaction in Own Shares and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.